CN116348468A - Cftr调节剂化合物、组合物及其用途 - Google Patents

Cftr调节剂化合物、组合物及其用途 Download PDF

Info

Publication number
CN116348468A
CN116348468A CN202180072298.5A CN202180072298A CN116348468A CN 116348468 A CN116348468 A CN 116348468A CN 202180072298 A CN202180072298 A CN 202180072298A CN 116348468 A CN116348468 A CN 116348468A
Authority
CN
China
Prior art keywords
optionally substituted
compound
alkyl
heterocycle
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180072298.5A
Other languages
English (en)
Chinese (zh)
Inventor
李铭宰
吴昌穆
林多美
金庆儿
李雪熙
郑日智
柳在垠
李周衍
全艺璘
权镇鲜
孙泰翼
金建熺
金正镐
尹钟旻
李真喜
尹洪哲
李政祐
朴俊泰
安敬美
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
S2c Biotech Co ltd
Original Assignee
Ildong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ildong Pharmaceutical Co Ltd filed Critical Ildong Pharmaceutical Co Ltd
Publication of CN116348468A publication Critical patent/CN116348468A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202180072298.5A 2020-10-23 2021-10-22 Cftr调节剂化合物、组合物及其用途 Pending CN116348468A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063104979P 2020-10-23 2020-10-23
US63/104,979 2020-10-23
PCT/IB2021/000710 WO2022084741A1 (en) 2020-10-23 2021-10-22 Cftr modulator compounds, compositions, and uses thereof

Publications (1)

Publication Number Publication Date
CN116348468A true CN116348468A (zh) 2023-06-27

Family

ID=81290147

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180072298.5A Pending CN116348468A (zh) 2020-10-23 2021-10-22 Cftr调节剂化合物、组合物及其用途

Country Status (16)

Country Link
US (2) US11827640B2 (enExample)
EP (1) EP4232451A4 (enExample)
JP (1) JP2023547389A (enExample)
KR (1) KR20230096026A (enExample)
CN (1) CN116348468A (enExample)
AR (1) AR123884A1 (enExample)
AU (1) AU2021363703A1 (enExample)
CA (1) CA3196061A1 (enExample)
CL (1) CL2023001139A1 (enExample)
CO (1) CO2023006647A2 (enExample)
IL (1) IL302247A (enExample)
MX (1) MX2023004712A (enExample)
PY (1) PY2193067A (enExample)
TW (1) TW202233620A (enExample)
UY (1) UY39482A (enExample)
WO (1) WO2022084741A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026007253A1 (zh) * 2024-07-05 2026-01-08 广东省科学院动物研究所 二氟甲氧基苯基类pde4抑制剂及其应用
CN121609673A (zh) * 2026-02-02 2026-03-06 五邑大学 一种pde4抑制剂及其制备方法和应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114380835B (zh) * 2022-01-06 2022-12-27 南京桦冠生物技术有限公司 一种7-(3,4-二甲氧苯基)-2-吡唑[1,5-a]嘧啶羧酸的制备方法
TW202425990A (zh) * 2022-11-02 2024-07-01 南韓商日東製藥股份有限公司 包含ｃｆｔｒ調節劑化合物之點眼用組成物

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070129383A1 (en) * 2003-10-17 2007-06-07 Hiroshi Kuramochi Substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative and use thereof
WO2008056176A1 (en) * 2006-11-10 2008-05-15 Scottish Biomedical Limited Pyrazolopyrimidines as phosphodiesterase inhibitors
CN101321763A (zh) * 2005-10-06 2008-12-10 先灵公司 作为蛋白激酶抑制剂的吡唑并[1,5-a]嘧啶
US20130143915A1 (en) * 2010-07-01 2013-06-06 Cellzome Limited Triazolopyridines as tyk2 inhibitors
WO2013087805A1 (en) * 2011-12-14 2013-06-20 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mglu5 receptors
EP2831074B1 (en) * 2012-03-29 2016-09-14 Boehringer Ingelheim International GmbH Novel pyrazolopyrimidines as metabotropic glutamate 5 receptor antagonists for the treatment of psychiatric diseases
WO2018078005A1 (en) * 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Amido-substituted azaspiro derivatives as tankyrase inhibitors
CN110573154A (zh) * 2017-02-06 2019-12-13 卡斯西部储备大学 调节短链脱氢酶活性的组合物和方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4178449A (en) 1978-04-17 1979-12-11 American Cyanamid Company Pyrazolo[1,5-a]pyrimidines and imidazo-[1,5-a]pyrimidines
US4281000A (en) 1979-07-09 1981-07-28 American Cyanamid Company Substituted pyrazolo (1,5-a)pyrimidines and their use as anxiolytic agents
AU651986B2 (en) 1991-04-22 1994-08-11 Otsuka Pharmaceutical Factory, Inc. Pyrazolo{1,5-a}pyrimidine derivative and anti-inflammatory containing the same
CA2465326C (en) * 2001-11-01 2011-03-29 Icagen, Inc. Pyrazolopyrimidines for decreasing ion flow through a voltage-dependent sodium channel
AU2003240488A1 (en) 2002-06-04 2003-12-19 Neogenesis Pharmaceuticals, Inc. Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents
JP2004170323A (ja) 2002-11-22 2004-06-17 Sumitomo Pharmaceut Co Ltd 皮膚疾患治療剤のスクリーニング方法
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
WO2004089471A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF
US20070270408A1 (en) 2003-04-11 2007-11-22 Novo Nordisk A/S Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines
WO2004089416A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent
US7498434B2 (en) 2004-01-14 2009-03-03 Mallinckrodt Inc Two-phase method for the synthesis of selected pyrazolopyrimidines
EP1778685B1 (de) 2004-08-02 2008-03-26 Schwarz Pharma Ag Carboxamide des indolizins und seiner aza- und diazaderivate
WO2006088246A1 (ja) 2005-02-18 2006-08-24 Takeda Pharmaceutical Company Limited Ｇｐｒ３４受容体機能調節剤
AR056876A1 (es) 2005-10-21 2007-10-31 Tanabe Seiyaku Co Compuestos de pirazolo[1-5-a]pirimidina, antagonistas de receptores canabinoides cb1, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades del sistema nervioso central, tales como trastornos psicoticos, neurologicos y similares
AR061793A1 (es) 2006-07-05 2008-09-24 Mitsubishi Tanabe Pharma Corp Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica
WO2008045664A2 (en) 2006-10-06 2008-04-17 Kalypsys, Inc. Heterocyclic pde4 inhibitors as antiinflammatory agents
CA2705303A1 (en) * 2007-11-07 2009-05-14 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
JP5637859B2 (ja) * 2007-12-13 2014-12-10 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 嚢胞性線維症膜コンダクタンスレギュレーターのモジュレーター
WO2010063487A1 (en) 2008-12-05 2010-06-10 Merz Pharma Gmbh & Co. Kgaa Pyrazolopyrimidines, a process for their preparation and their use as medicine
JP5578490B2 (ja) 2008-12-26 2014-08-27 味の素株式会社 ピラゾロピリミジン化合物
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
WO2014144455A1 (en) 2013-03-15 2014-09-18 Epizyme, Inc. 1 -phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof
CN103923105B (zh) 2014-04-17 2016-08-24 北京大学 2-中氮茚甲酰胺类化合物及其制备和用途
WO2016012896A1 (en) * 2014-07-24 2016-01-28 Pfizer Inc. Pyrazolopyrimidine compounds
JP2018076234A (ja) 2015-03-16 2018-05-17 大正製薬株式会社 ピラゾロ［１，５−ａ］ピリミジン化合物
JP6894902B2 (ja) 2015-12-24 2021-06-30 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Ｃｆｔｒ制御因子及びこの使用方法
CN107286156A (zh) 2016-04-05 2017-10-24 江苏新元素医药科技有限公司 新型urat1抑制剂及其在医药上的应用
WO2018226150A1 (en) 2017-06-05 2018-12-13 Medivir Aktiebolag Pyrazolopyrimidine as malt-1 inhibitors

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070129383A1 (en) * 2003-10-17 2007-06-07 Hiroshi Kuramochi Substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative and use thereof
CN101321763A (zh) * 2005-10-06 2008-12-10 先灵公司 作为蛋白激酶抑制剂的吡唑并[1,5-a]嘧啶
WO2008056176A1 (en) * 2006-11-10 2008-05-15 Scottish Biomedical Limited Pyrazolopyrimidines as phosphodiesterase inhibitors
US20130143915A1 (en) * 2010-07-01 2013-06-06 Cellzome Limited Triazolopyridines as tyk2 inhibitors
WO2013087805A1 (en) * 2011-12-14 2013-06-20 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mglu5 receptors
EP2831074B1 (en) * 2012-03-29 2016-09-14 Boehringer Ingelheim International GmbH Novel pyrazolopyrimidines as metabotropic glutamate 5 receptor antagonists for the treatment of psychiatric diseases
WO2018078005A1 (en) * 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Amido-substituted azaspiro derivatives as tankyrase inhibitors
CN110573154A (zh) * 2017-02-06 2019-12-13 卡斯西部储备大学 调节短链脱氢酶活性的组合物和方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHU ZHOU，等: "Structure-based discovery of new maternal embryonic leucine zipper kinase inhibitors", 《ORG. BIOMOL. CHEM.》, vol. 16, 31 December 2018 (2018-12-31), pages 1489 - 1495, XP055749148, DOI: 10.1039/C7OB02344H *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026007253A1 (zh) * 2024-07-05 2026-01-08 广东省科学院动物研究所 二氟甲氧基苯基类pde4抑制剂及其应用
CN121609673A (zh) * 2026-02-02 2026-03-06 五邑大学 一种pde4抑制剂及其制备方法和应用

Also Published As

Publication number Publication date
TW202233620A (zh) 2022-09-01
MX2023004712A (es) 2023-05-09
AU2021363703A9 (en) 2025-01-09
US20230080486A1 (en) 2023-03-16
JP2023547389A (ja) 2023-11-10
KR20230096026A (ko) 2023-06-29
IL302247A (en) 2023-06-01
UY39482A (es) 2022-05-31
US20240199623A1 (en) 2024-06-20
AR123884A1 (es) 2023-01-18
CA3196061A1 (en) 2022-04-28
PY2193067A (es) 2022-06-20
WO2022084741A1 (en) 2022-04-28
CO2023006647A2 (es) 2023-05-29
EP4232451A1 (en) 2023-08-30
EP4232451A4 (en) 2024-11-06
US11827640B2 (en) 2023-11-28
AU2021363703A1 (en) 2023-06-22
CL2023001139A1 (es) 2023-11-17

Similar Documents

Publication Publication Date Title
CN110719902B (zh) Ssao抑制剂
CN116348468A (zh) Cftr调节剂化合物、组合物及其用途
EP2649075B1 (en) Substituted pyrazolopyrimidines as glucocerebrosidase activators
CA2957046C (en) Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
CN113811300A (zh) Tead转录因子的新型小分子抑制剂
RU2642777C2 (ru) Производные 2-аминопиразина в качестве ингибиторов csf-1r киназы
JP7350759B2 (ja) ニューロトロフィンに関連する疾患を治療するためのトリアジン誘導体
JP2016164157A (ja) ビシクロ［３．２．１］オクチルアミド誘導体およびその使用
US20190389865A1 (en) SUBSTITUTED PYRROLO[1,2-a]TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
WO2012020725A1 (ja) Ｎｐｙ ｙ５受容体拮抗作用を有するヘテロ環誘導体
CN112513032B (zh) 作为trk受体的调节剂的4-取代的苯基-1,3,5-三嗪衍生物
FR2891829A1 (fr) Derives de la 4-amino-quinazoline, leur preparation et leur application en therapeutique
WO2020103939A1 (zh) 三唑并环类化合物、其制备方法、中间体和应用
TW202529754A (zh) Tyk2抑制劑及其用途
AU2024264337A1 (en) Tricyclic fused imidazole compounds as cd38 modulators and uses thereof
AU2020388645B2 (en) TRPV4 receptor ligands
WO2023067388A1 (en) Uses of cftr modulator and/or pde4 inhibitor compounds
HK40089053A (zh) Cftr调节剂化合物、组合物及其用途
CN113943251B (zh) 双环庚烯基氨基取代的氮杂芳环类化合物及其医药用途
CN120136847A (zh) 嘧啶二酮衍生物及其制备方法和应用
WO2024148184A1 (en) Compounds and processes for the preparation of jak inhibitors
WO2026037286A1 (zh) 一类cGAS抑制剂、其制备方法和用途
CN120112520A (zh) 经取代的苯基苯磺酰胺衍生物及其用途
HK1147262A (en) 4,5-dihydro-(1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40089053

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20260204

Address after: Incheon Wide Area City, Korea

Applicant after: S2C Biotech Co.,Ltd.

Country or region after: Republic of Korea

Address before: Seoul, South Kerean

Applicant before: ILDONG PHARM Co.,Ltd.

Country or region before: Republic of Korea

TA01 Transfer of patent application right